Le Lézard
Classified in: Health
Subject: SVY

Healthcare Analytical Testing Services Market Worth 5.97 Billion USD by 2023


PUNE, India, March 20, 2018 /PRNewswire/ --

According to a new market research report "Healthcare Analytical Testing Services Market by Type (Method Validation, Environmental Monitoring, Bioanalytical Services, Stability, Raw Materials, & Microbial Testing), End User (Pharmaceutical, Medical Device Companies, CRO) - Global Forecast to 2023", published by MarketsandMarketstm, the market is expected to reach USD 5.97 Billion by 2023 from an estimated USD 3.43 Billion in 2018, at a CAGR of 11.7%. The shift of focus towards analytical testing of biologics and biosimilars, increasing outsourcing of analytical testing by pharmaceutical companies, increasing acceptance of the QbD approach in pharma research/manufacturing, and adoption of FTE contracts in R&D outsourcing are the major factors driving the growth of the Healthcare Analytical Testing Services Market.

     (Logo: http://photos.prnewswire.com/prnh/20160303/792302 )

Browse 286 market data Tables and 36 Figures spread through 296 Pages and in-depth TOC on "Healthcare Analytical Testing Services Market"

https://www.marketsandmarkets.com/Market-Reports/healthcare-analytical-testing-services-market-108923833.html

Early buyers will receive 10% customization on this report 

"By type, the bioanalytical testing segment accounted for the largest share of the Healthcare Analytical Testing Services Market in 2017."

On the basis of type, the bioanalytical testing segment accounted for the largest share of the global Healthcare Analytical Testing Services Market. The large share of this segment is due to increasing number of drugs in the biopharmaceutical pipeline and the growing biopharmaceutical industry.

"By end user, the pharmaceutical and biopharmaceutical companies segment held the largest market share of the Healthcare Analytical Testing Services Market in 2017."

Based on end user, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the Healthcare Analytical Testing Services Market. The large share of this segment can be attributed to increasing outsourcing of analytical testing services by pharmaceutical and biopharmaceutical companies to boost profit margins, avoid high capital expenditure, and reduce the time required to validate the process and product.

Ask for PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=108923833

"North America dominated the market in 2017." 

North America accounted for the largest share of the Healthcare Analytical Testing Services Market in 2017, followed by Europe and Asia Pacific. The presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, growth in the biosimilars and generics markets, increasing number of analytical testing service providers, and rising outsourcing of analytical testing by biopharmaceutical companies are the major factors responsible for the large share of North America in the global Healthcare Analytical Testing Services Market.

The prominent players in the global Healthcare Analytical Testing Services Market are Eurofins Scientific (Luxembourg), Wuxi PharmaTech (China), and Charles River Laboratories (US) held the major share of the Healthcare Analytical Testing Services Market and will continue to dominate the market between 2018 and 2023. Other major players operating in this market are Almac Group (UK), Exova Group (UK), PPD (US), Source BioScience (UK), Anabiotec (Belgium), Intertek Group (UK), and BioReliance (US).

Know more about the Healthcare Analytical Testing Services Market: 

https://www.marketsandmarkets.com/Market-Reports/healthcare-analytical-testing-services-market-108923833.html

About MarketsandMarketstm  

MarketsandMarketstm provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarketstm for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarketstm are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarketstm now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarketstm is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.


Contact:
Mr. Salgarkar
MarketsandMarketstm INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


SOURCE MarketsandMarkets


These press releases may also interest you

at 16:20
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity ...

at 16:20
Edwards Lifesciences today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales...

at 16:16
A functional assessment of Bacillus subtilis PLSSC (SEBtilistm) demonstrated its antimicrobial activity and capability to offer health benefits through industrial processing and the digestion process, showing its value-add in functional foods,...

at 16:15
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for...

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...



News published on and distributed by: